References
- Taveira-DaSilva AM, Moss J. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clinical Epidemiology. 2015;7: 249–257. doi:10.2147/CLEP.S50780.
- Harknett EC, Chang WY, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. Quarterly Journal of Medicine. 2011;104(11): 971–979. doi:10.1093/QJMED/HCR116.
- Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respiratory Medicine. 2002;96(1): 1–6. doi:10.1053/RMED.2001.1207.
- Ryu JH, Moss J, Beck GJ, Lee JC, BrownKK, ChapmanJT, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. American Journal of Respiratory and Critical Care Medicine. 2006;173(1): 105–111. doi:10.1164/RCCM.200409-1298OC.
- Johnson SR, Cordier JF, Lazor R, Cottin V, Costabe lU, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. European Respiratory Journal. 2010;35(1): 14–26. doi:10.1183/09031936.00076209.
- Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse cystic lung disease. Part I. American Journal of Respiratory and Critical Care Medicine. 2015;191(12): 1354–1366. doi:10.1164/rccm.201411-2094CI.
- Seaman DM, Meyer CA, Gilman MD, McCormack FX. Diffuse cystic lung disease at high-resolution CT. AJR American Journal of Roentgenology. 2011;196(6): 1305–1311. doi:10.2214/AJR.10.4420.
- Xu KF, Xu W, Liu S, Yu J, Tian X, Yang Y, et al. Lymphangioleiomyomatosis. Seminars in Respiratory and Critical Care Medicine. 2020;41(2): 256–268. doi:10.1055/s-0040-1702195.